Home Cart Sign in  
Chemical Structure| 747-36-4 Chemical Structure| 747-36-4

Structure of Hydroxychloroquine sulfate
CAS No.: 747-36-4

Chemical Structure| 747-36-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hydroxychloroquine sulfate is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR)7/9.

Synonyms: HCQ sulfate; Hydroxychloroquine(sulfate)(CRM); HCQ

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hydroxychloroquine sulfate

CAS No. :747-36-4
Formula : C18H28ClN3O5S
M.W : 433.95
SMILES Code : CCN(CCO)CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C.O=S(O)(O)=O
Synonyms :
HCQ sulfate; Hydroxychloroquine(sulfate)(CRM); HCQ
MDL No. :MFCD00078203
InChI Key :JCBIVZZPXRZKTI-UHFFFAOYSA-N
Pubchem ID :12947

Safety of Hydroxychloroquine sulfate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319
Precautionary Statements:P305+P351+P338

Related Pathways of Hydroxychloroquine sulfate

pyroptosis
TLR

Isoform Comparison

Biological Activity

Target
  • Autophagy

In Vitro:

Cell Line
Concentration Treated Time Description References
hFob1.19 cells 10 µM 12 h Inhibited autophagy, reduced HG-induced lipid peroxide and ROS accumulation PMC10500928
ZR-75-1 ICI-R cells 1 μM 6 days To evaluate the effect of hydroxychloroquine on antiestrogen sensitivity, results showed that HCQ enhanced antiestrogen-mediated cell death. PMC4073207
MCF7-RR cells 1 μM 6 days To evaluate the effect of hydroxychloroquine on antiestrogen sensitivity, results showed that HCQ enhanced antiestrogen-mediated cell death. PMC4073207
LCC9 cells 1 μM 6 days To evaluate the effect of hydroxychloroquine on antiestrogen sensitivity, results showed that HCQ enhanced antiestrogen-mediated cell death. PMC4073207
MCF7 cells 1 μM 6 days To evaluate the effect of hydroxychloroquine on antiestrogen sensitivity, results showed that HCQ enhanced antiestrogen-mediated cell death. PMC4073207
Patient-derived organoids 1uM 7 days To evaluate the effect of hydroxychloroquine on patient-derived organoids from gastric cancer peritoneal metastasis, results showed that hydroxychloroquine significantly induced organoid apoptosis. PMC9929081
3T3-L1 adipocytes 50 μM 24 h To evaluate the effect of hydroxychloroquine on inflammatory and metabolic gene expression in adipocytes activated by serum from RA patients. Results showed that hydroxychloroquine significantly reduced mRNA expression of TNF-α and IL-1β and modulated the expression of genes related to lipid and glucose metabolism. PMC8549628
H1975 cells 10 μM 16 h To investigate the effect of hydroxychloroquine in combination with erlotinib or paclitaxel on EGFR TKI-resistant cells. Results showed that hydroxychloroquine combined with erlotinib or paclitaxel reduced EGFR activation and AKT activity. PMC7052910
Peripheral blood mononuclear cells (PBMCs) 100 μM 24 h To investigate the inhibitory effect of hydroxychloroquine on trained immunity. Results showed hydroxychloroquine inhibited HKCA-induced trained immune responses, including responses to virus-like stimuli and interferons. PMC7762774

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Athymic nude mice LCC9 and MCF7-RR cells mammary fat pad xenograft model HCQ: drinking water; TAM: diet; ICI: subcutaneous injection 0.29 mg/ml (drinking water) 5 weeks To evaluate the effect of hydroxychloroquine combined with antiestrogen therapy on resensitizing resistant breast tumors. Results showed that HCQ combined with TAM significantly reduced tumor size and weight, while the ICI+HCQ combination was less effective. PMC4073207
NOD/SCID mice Gastric cancer peritoneal metastasis model Intraperitoneal injection 30 μg/g Every 3 days for 3 weeks To evaluate the effect of hydroxychloroquine on gastric cancer peritoneal metastasis in mice, results showed that hydroxychloroquine significantly inhibited peritoneal metastasis. PMC9929081
Nude mice H292 lung cancer xenograft model Intraperitoneal injection 60 mg/kg Once daily until tumor volume reached 1500 mm3 or 10% weight loss To evaluate the effect of hydroxychloroquine on the growth of H292 wild-type and ATG7 knockout tumors. Results showed that HCQ inhibited the growth of WT tumors but had no significant effect on ATG7 knockout tumors. PMC7233142
C57BL/6 mice Obese collagen-induced arthritis (CIA) model Oral 60 mg/kg Once daily for 15 days To evaluate the effect of hydroxychloroquine on body weight, insulin resistance, and adipose tissue inflammation in obese CIA mice. Results showed that hydroxychloroquine significantly reduced body weight and insulin resistance and improved metabolic and inflammatory status in adipose tissue. PMC8549628
Nude mice HCCLM3 xenograft model Intraperitoneal injection 50 mg/kg Not specified Combination therapy with lenvatinib and hydroxychloroquine significantly inhibited HCC growth and metastasis, prolonging survival. PMC7807703
Mice CCSP-rtTA-EGFR L858R-T790M transgenic mice Oral 180 mg/kg Daily administration for 30 days To evaluate the effect of hydroxychloroquine in combination with gefitinib or paclitaxel on EGFR TKI-resistant tumors. Results showed that hydroxychloroquine combined with gefitinib or paclitaxel significantly reduced tumor volume and cell proliferation. PMC7052910
Mice IMQ-induced psoriasis-like skin lesion model Gavage 20 mg/kg Once daily for 7 days To investigate the effect of TLR7 inhibitor (hydroxychloroquine) on IMQ-induced psoriasis-like skin lesions, results showed that hydroxychloroquine reduced the severity of skin lesions and inflammatory responses. PMC10170143
Mice Polytrauma model and DVT model Intraperitoneal injection 50mg/kg Single dose, lasting 30 minutes To assess the effect of HCQ on PEV release and thrombus formation, results showed HCQ significantly reduced PEV release and decreased thrombus burden PMC6773503
Mice IGF1Rtg mice and dnPI3K mice Intraperitoneal injection 60 mg/kg Daily for 4 weeks To evaluate the effect of autophagy inhibition on cardiac function in dnPI3K mice. Results showed that HCQ treatment abolished the differences in cardiac function between dnPI3K and WT mice. PMC9203038

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02603146 Healthy Participants ... More >> Rheumatoid Arthritis (RA) Prevention Less << Phase 2 Recruiting March 2020 -
NCT01897116 Melanoma Phase 1 Completed - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00430807 Giant Cell Arteritis Phase 3 Completed - France ... More >> Hospital Agen, France, 47923 Hospital Albi, France, 81000 Hospital Auch Auch, France, 32008 Hospital Avignon Avignon, France, 84902 University Hospital Besançon Besançon, France, 25030 Hospital Béziers Beziers, France, 34525 University Hospital Côte de Nacre Caen, France, 14033 University Hospital Dijon Dijon, France, 21035 Hospital Foix, France, 09017 Hospital Lavaur, France, 81500 University Hospital Dupuytren Limoges, France, 87042 Hospital Lisieux, France, 14100 Hospital Lourdes, France, 65107 Hospital Mazamet, France, 81200 Hospital Montauban, France, 82013 University Hospital Nantes, France, 44035 Saint Louis Hospital Paris, France, 75010 University Hospital Saint Antoine Paris, France, 75012 University Hospital Bichat Paris, France, 75018 Hospital Suresnes Suresnes, France, 92151 University Hospital Toulouse Toulouse, France, 31059 University Hospital Toulouse, France, 31059 University Hospital Bretonneau Tours, France, 37044 Less <<
NCT00909831 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Unknown - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-4283 Less <<
NCT00176982 Alopecia Areata Phase 4 Completed - United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, New York State University of New York at Stony Brook Stonybrook, New York, United States, 11790 Less <<
NCT00413361 Systemic Lupus Erythematosus Phase 4 Completed - France ... More >> Chu Pitie Salpetriere Paris, France, 75013 Hopital la Pitié Salpétrière Assistance Publique Paris, France, 75013 Less <<
NCT01549184 - Completed - -
NCT01649947 Non-small Cell Lung Cancer ... More >> Advanced Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Less << Phase 2 Completed - United States, New Jersey ... More >> Robert Wood Johnson University Hospital at Hamilton Hamilton, New Jersey, United States, 08690 Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Less <<
NCT00568880 Multiple Myeloma and Plasma Ce... More >>ll Neoplasm Less << Phase 1 Phase 2 Unknown - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104-4283 Contact: Clinical Trials Office - Abramson Cancer Center of the Univers    800-474-9892 Less <<
NCT03344172 Pancreatic Cancer Resectable Phase 2 Recruiting January 1, 2021 United States, Pennsylvania ... More >> UPMC Hillman Cancer Center Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Summer Drummond, BSN, RN, CCRC    412-623-2677    drummondsl@upmc.edu    Contact: Barbara Stadterman, MPH, MSCR, CCRP    412-647-5554    stadtermanbm@upmc.edu    Principal Investigator: Nathan Bahary, MD, PhD Less <<
NCT01689987 Recurrent Plasma Cell Myeloma ... More >> Refractory Plasma Cell Myeloma Less << Phase 1 Completed - United States, Oregon ... More >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239 Less <<
NCT01006369 Colorectal Cancer Phase 2 Completed - United States, New Jersey ... More >> Cooper Hospital/University Medical Center Camden, New Jersey, United States, 08103 Cancer Institute of New Jersey at Hamilton Hamilton, New Jersey, United States, 08690 Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 New Jersey Medical School/The University Hospital Cancer Center Newark, New Jersey, United States, 07103 Less <<
NCT01783106 Crohn's Disease Phase 2 Recruiting December 31, 2019 United Kingdom ... More >> Royal Liverpool and Broadgreen Unversity Hospitals Trust Recruiting Liverpool, Merseyside, United Kingdom, L7 8XP Contact: Kate Martin, SRN    0151 706 4074    kate.martin@rluhbt.nhs.uk    Sub-Investigator: Jonathan M Rhodes, MD          Principal Investigator: Sreedar Subramanian, MD Less <<
NCT00311883 Cystic Fibrosis Phase 1 Completed - United States, Tennessee ... More >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 Less <<
NCT01602588 Glioblastoma Phase 2 Completed - United Kingdom ... More >> St James's University Hospital Leeds, West Yorkshire, United Kingdom, LS9 7TF Glan Clwyd Hospital Bodelwyddan, United Kingdom, LL18 5UJ Addenbrooke's Hospital Cambridge, United Kingdom, CB2 0QQ Ninewells Hospital Dundee, United Kingdom Beatson West of Scotland Cancer Centre Glasgow, United Kingdom, G12 0YN Royal Surrey County Hospital Guildford, United Kingdom, GU2 7XX University College Hospital London, United Kingdom, NW1 2BU Guy's and St Thomas's Hospitals London, United Kingdom, SE1 9RT Charing Cross Hospital London, United Kingdom, w6 8RF Christie Hospital Manchester, United Kingdom, M20 4BX James Cook University Hospital Middlesbrough, United Kingdom, TS4 3BW Freeman Hospital Newcastle, United Kingdom, NE7 7DN Norfolk & Norwich University Hospitals Norwich, United Kingdom, NR4 7UY The Royal Preston Hospital Preston, United Kingdom, PR2 9HT Royal Stoke University Hospital Stoke-on-Trent, United Kingdom, ST4 6QG Less <<
NCT01145196 - Recruiting - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010    prpl@cc.nih.gov Less <<
NCT03305263 Recurrent Pregnancy Loss Phase 3 Recruiting January 2023 Denmark ... More >> Rigshospitalet Recruiting København, Denmark, 2100 Contact: Louise Lunøe, Nurse    +4535458486    anne.louise.lunoee@regionh.dk    Contact: Henriette S Nielsen, MD    +4535457515    henriette.svarre.nielsen@regionh.dk Less <<
NCT00102557 Lichen Planus, Oral Phase 2 Completed - United States, Maryland ... More >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Less <<
NCT01067417 HIV Infections Phase 2 Unknown February 2011 -
NCT00813423 Adult Solid Neoplasm Phase 1 Active, not recruiting - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT02316340 Colorectal Cancer Phase 2 Recruiting June 2020 United States, Texas ... More >> Cancer Therapy and Research Center University of Texas Health Science Center San Antonio Recruiting San Antonio, Texas, United States, 78229 Contact: Epp Goodwin    210-450-5798    CTRCReferral@uthscsa.edu    Principal Investigator: Devalingam Mahalingam, MD, PhD Less <<
NCT00873496 - Completed - Turkey ... More >> Ege University School of Dentistry Izmir, Bornova, Turkey, 35100 Less <<
NCT02444728 Thrombocytopenia Phase 3 Unknown December 2018 China, Anhui ... More >> the Affiliated Hospital to Bangbu Medical University Recruiting Bangbu, Anhui, China, 233000 Contact: Zhijun Li, MD    13955289810    zhijun.li@cstar.org.cn    Contact: Changhao Xie, MD    15255227208    uglboy2002@126.com    China, Hebei Hebei Provincial Hospital Recruiting Shijiazhuang, Hebei, China, 050051 Contact: Fengxiao Zhang, MD    13722879168    fengxiao.zhang@cstar.org.cn    Contact: Wei Lin, MD    17736909239    linwei272@163.com    China, Hunan the First Affiliated Hospital of Xiangya Medical University Recruiting Changsha, Hunan, China, 410000 Contact: Xiaoxia Zuo, MD    86-13787216257    xiaoxia.zuo@cstar.org.cn    Contact: jing Huang, MD    15874869645    jilianhj@csu.edu.cn    China, Inner Mongolia the Affiliated Hospital of Inner Mongolia Medical University Recruiting Huhehaote, Inner Mongolia, China, 010050 Contact: Hongbin Li, MD    13948536552    hongbin.li@cstar.org.cn    Contact: Ning Tie, MD    13948610720    tieting@126.com    China, Jilin Sino-Japanese Friendship Hospital of Jilin University Not yet recruiting Changchun, Jilin, China, 410008 Contact: Liqi Bi, MD    13578879099    liqi.bi@cstar.org.cn    Contact: Cuili Ma, MD    13664438195    macuili@yeah.net    China, Shanxi the Affiliated Hospital of Xian Communication Hospital Not yet recruiting Xian, Shanxi, China, 710000 Contact: Lan He, MD    13809156236    lan.he@cstar.org.cn    Contact: Bomiao Ju, MD    18792778105    18792778105@163.com    Xijing Hospital Recruiting Xian, Shanxi, China, 710032 Contact: Ping Zhu, MD    13700235112    ping.zhu@cstar.org.cn    Contact: Weitong Chen, MD    15771943030    chenweitong0818@163.com    China, Xinjiang Xinjiang Provincial Hospital Not yet recruiting Urumqi, Xinjiang, China, 830001 Contact: Lijun Wu, MD    13999265917    lijun.wu@cstar.org.cn    Contact: Cainan Luo, MD    15739551667    future_tense@sina.com    China, Yunnan the Affiliated Hospital of Kunming Medical University Recruiting Kunming, Yunnan, China, 650032 Contact: Jian Xu, MD    13888566797    jian.xu@cstar.org.cn    Contact: Shu Li, MD    15198785584    gglis@126.com    China Beijng Hospital Not yet recruiting Beijing, China, 100006 Contact: Cibo Huang, MD    86-10-86372388    cibo.huang@cstar.org.cn    Beijing Chaoyang Hospital Recruiting Beijing, China, 100020 Contact: Yi Zheng, MD    13911170090    yi.zheng@cstar.org.cn    Contact: Yongfeng Zhang, MD    13671239495    zyf760116@sina.com    China-Japan Friendship Hospital Not yet recruiting Beijing, China, 100029 Contact: Gaochun Wang, MD    13910729602    guochun.wang@cstar.org.cn    Contact: Li Ma, MD    13910289103    marryma@vip.sina.com    Peking Union Medical College Hospital Recruiting Beijing, China, 100032 Contact: Xinping Tian, MD    86-13691165939    tianxp6@126.com    Contact: Ai Xu, Coordinator    86-15910602883    1989xuai@sina.cn    Sub-Investigator: Mengtao Li, MD          Beijing Xuanwu Hospital Recruiting Beijing, China, 100053 Contact: Xiaoxia Li, MD    13501164945    xiaoxia.li@cstar.org.cn    Contact: Yi Zhao, MD    13811038669    zhaoyi_peking@163.com    General Hospital of Tianjing Medical University Recruiting Tianjin, China, 300052 Contact: Wei Wei, MD    13920182411    wei.wei@cstar.org.cn    Contact: Na Zhang, MD    13820489562    lunazhang22@hotmail.com Less <<
NCT03400865 Resistance, Disease ... More >> Prolactinoma Less << Not Applicable Not yet recruiting December 30, 2020 China, Beijing ... More >> Beijing Tiantan Hospital Not yet recruiting Beijing, Beijing, China China, Shanghai Huashan Hospital Not yet recruiting Shanghai, Shanghai, China, 200025 Ruijin Hosipital Enrolling by invitation Shanghai, Shanghai, China, 200025 China Chinese PLA General Hospital Not yet recruiting Beijing, China Peking Union Medical College Hospital Recruiting Beijing, China Xinqiao Hospital of Chongqing Not yet recruiting Chongqing, China First Affiliated Hospital of Fujian Medical Recruiting Fujian, China First Hospital of China Medical University Not yet recruiting Shenyang, China First Affiliated Hospital of Wenzhou Medical Univeristy Recruiting Wenzhou, China Less <<
NCT03180190 - Not yet recruiting July 28, 2018 -
NCT00728845 Lung Cancer Phase 1 Phase 2 Terminated(Slow accrual) - United States, New Jersey ... More >> Cancer Institute of New Jersey at Hamilton Hamilton, New Jersey, United States, 08690 Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 Less <<
NCT01396200 Myeloma Early Phase 1 Completed - United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00728845 - Terminated(Slow accrual) - -
NCT00786682 - Terminated(Lack of improved ef... More >>ficacy compared to historical controls, competing studies) Less << - -
NCT01978184 Pancreatic Cancer Phase 2 Active, not recruiting November 2018 United States, Pennsylvania ... More >> Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT00786682 Prostate Cancer Phase 2 Terminated(Lack of improved ef... More >>ficacy compared to historical controls, competing studies) Less << - United States, New Jersey ... More >> Cancer Institute of New Jersey at Hamilton Hamilton, New Jersey, United States, 08690 Mountainside Hospital Montclair, New Jersey, United States, 07042 Carol G. Simon Cancer Center at Morristown Memorial Hospital Morristown, New Jersey, United States, 07962 Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 St. Peters University Hospital New Brunswick, New Jersey, United States, 08903 Overlook Hospital Summit, New Jersey, United States, 07901 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT01828476 Prostate Cancer Phase 2 Terminated(The Investigator le... More >>ft the organization.) Less << - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Less <<
NCT01828476 - Terminated(The Investigator le... More >>ft the organization.) Less << - -
NCT01480154 Adult Solid Neoplasm ... More >> Hormone-Resistant Prostate Carcinoma Recurrent Melanoma Recurrent Prostate Carcinoma Recurrent Renal Cell Carcinoma Stage IIIA Cutaneous Melanoma AJCC v7 Stage IIIB Cutaneous Melanoma AJCC v7 Stage IIIC Cutaneous Melanoma AJCC v7 Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IV Prostate Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 Less << Phase 1 Active, not recruiting - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT01495403 Liver Cirrhosis ... More >> Muscle Cramps Less << Early Phase 1 Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00809237 Non-small Cell Lung Cancer Phase 1 Phase 2 Unknown November 2014 Singapore ... More >> National University Hospital Recruiting Singapore, Singapore, 119074 Contact: Tan Min Chin, MD    65-67724140    Tan_Min_CHIN@nuhs.com.sg    Contact: Boon Cher Goh, MD    65-67724140    Boon_Cher_GOH@nuhs.com.sg    Principal Investigator: Tan Min Chin, MD Less <<
NCT02910076 Diabetes Type Two Phase 1 Phase 2 Unknown - -
NCT03030118 Systemic Lupus Erythematosus Phase 2 Recruiting January 2022 United States, California ... More >> Cedars-Sinai Medical Center Recruiting Los Angeles, California, United States, 90048 Contact: Mariko Ishimori, MD       mariko.ishimori@cshs.org    Contact: Bonnie Paul    310-423-2422    Bonnie.Paul@cshs.org    Sub-Investigator: Daniel Wallace, MD          United States, Oklahoma Oklahoma Medical Research Foundation Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Judith James, MD, PhD    405-271-4987    Judith-James@omrf.org    Contact: Cristina Arriens, MD    405-271-7745    cristina-Arriens@omrf.org    United States, Pennsylvania Penn State MS Hershey Medical Center Recruiting Hershey, Pennsylvania, United States, 17033 Contact: Nancy J Olsen, MD    717-531-4921    nolsen@hmc.psu.edu    Contact: Jamie M Carter, LPN    7175314921    jcarter3@hmc.psu.edu    United States, South Carolina Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29425 Contact: Diane Kamen, MD MS       lupusresearch@musc.edu    United States, Texas UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390 Contact: David R Karp, MD PhD    214-648-9110    david.karp@utsouthwestern.edu    Contact: Azza Badr, MBBS    2146487219    azza.mutwally@utsouthwestern.edu    Sub-Investigator: Benjamin F Chong, MD Less <<
NCT00765765 - Terminated(Slow accrual) - -
NCT00765765 Breast Cancer Phase 1 Phase 2 Terminated(Slow accrual) - United States, New Jersey ... More >> Cancer Institute of New Jersey at Hamilton Hamilton, New Jersey, United States, 08690 Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States, 08903 Less <<
NCT03085940 Rheumatoid Arthritis Not Applicable Completed - Indonesia ... More >> Ciptomangunkusumo Hospital Jakarta, Indonesia, 10430 Less <<
NCT02421575 Prostate Carcinoma Early Phase 1 Terminated(slow accrual) - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT01417403 Bone Metastases ... More >> Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Terminated(Recently published ... More >>data that has shown HCQ to be safe when combined with chemo and or radiation at even higher doses than what is used in this study.) Less << - United States, Virginia ... More >> Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT01026844 Non-small Cell Lung Cancer Phase 1 Terminated(slow enrollment) - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT01026844 - Terminated(slow enrollment) - -
NCT00977470 Non-small Cell Lung Cancer Phase 2 Active, not recruiting December 2017 United States, California ... More >> Stanford Cancer Institute Stanford, California, United States, 94305 United States, Connecticut Yale Cancer Center New Haven, Connecticut, United States, 06519 United States, Maryland University of Maryland Baltimore, Maryland, United States, 21201 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT03025087 Individuals Undergoing Cardiac... More >> and General Surgery Less << Phase 4 Recruiting March 2020 United States, North Carolina ... More >> Duke Health Recruiting Durham, North Carolina, United States, 27710 Contact: Tiffany Bisanar, RN, BSN    919-681-0866    tiffany.bisanar@duke.edu    Principal Investigator: Joseph P Mathew, MD Less <<
NCT03592823 Atrial Fibrillation Phase 4 Recruiting August 1, 2020 China, Heilongjiang ... More >> Electrocardiograph Recruiting Harbin, Heilongjiang, China, 150001 Contact: Jing Shi, MD    86-451-85555672    yidashijing@163.com Less <<
NCT00977470 - Active, not recruiting - -
NCT01645176 Osteoarthritis of the Knee Phase 2 Completed - United States, California ... More >> Stanford University Stanford, California, United States, 94305 Less <<
NCT01634893 Refractory or Relapsed Solid T... More >>umors Less << Phase 1 Completed - United States, Texas ... More >> Cancer Therapy and Research Center at UTHSCSA San Antonio, Texas, United States, 78229 Less <<
NCT01023737 Malignant Solid Tumour Phase 1 Active, not recruiting September 2020 United States, Texas ... More >> Cancer Therapy & Research Center University of Texas Health Science Center San Antonio San Antonio, Texas, United States, 78229 Less <<
NCT03513211 Prostate Cancer Phase 1 Phase 2 Recruiting March 30, 2021 Australia, New South Wales ... More >> St Vincent's Hospital Recruiting Darlinghurst, New South Wales, Australia, 2010 Contact: Robert Kent    61 2 9355 5611    svhs.cancerresearch@svha.org.au Less <<
NCT01645176 - Completed - -
NCT03774472 Anatomic Stage I Breast Cancer... More >> AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Estrogen Receptor Positive HER2/Neu Negative MKI67 Positive Postmenopausal Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8 Less << Phase 1 Phase 2 Recruiting December 31, 2019 United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Debasish Tripathy    713-794-4385       Principal Investigator: Debasish Tripathy Less <<
NCT03015324 Solid Tumor Phase 1 Recruiting September 2028 United States, Kentucky ... More >> University of Kentucky Markey Cancer Center Recruiting Lexington, Kentucky, United States, 40536 Contact: Peng Wang, MD,PhD    859-393-3179    p.wang@uky.edu Less <<
NCT03754179 Melanoma Phase 1 Phase 2 Recruiting December 1, 2020 Belgium ... More >> UZ Brussel Recruiting Jette, Brabant, Belgium, 1090 Contact: Bart Neyns, Phd,Md    0032(0)2477 64 15    bart.neyns@uzbrussel.be    Principal Investigator: Bart Neyns, Phd,Md Less <<
NCT01128296 Pancreatic Cancer Phase 1 Phase 2 Active, not recruiting March 2018 United States, Pennsylvania ... More >> UPCI/UPMC Cancer Centers Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT03598595 Recurrent Osteosarcoma ... More >> Refractory Osteosarcoma Less << Phase 1 Phase 2 Not yet recruiting March 2, 2020 United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: John A. Livingston    713-792-3626       Principal Investigator: John A. Livingston Less <<
NCT02200146 Pulmonary Sarcoidosis Phase 3 Completed - Italy ... More >> Università degli Studi di Milano - Bicocca Milano, Italy, 20126 Less <<
NCT03687905 - Recruiting September 30, 2019 Egypt ... More >> Fatma Gheet Recruiting Tanta, Egypt Contact: Fatma S Gheet, M.B.,BCh    +201148157993    fatmagheet@gmail.com Less <<
NCT01128296 - Active, not recruiting - -
NCT02232243 Solid Tumor Phase 1 Active, not recruiting December 2018 United States, Kentucky ... More >> University of Kentucky, Markey Cancer Center Lexington, Kentucky, United States, 40536 Less <<
NCT01550367 Metastatic Renal Cell Carcinom... More >>a Less << Phase 1 Phase 2 Active, not recruiting September 2018 United States, Illinois ... More >> Loyola University Chicago Maywood, Illinois, United States, 60153 United States, Indiana Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New Hampshire Dartmouth-Hitchcock Medical Center Hanover, New Hampshire, United States, 03755 United States, Ohio The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Oregon Providence Health & Services Portland, Oregon, United States, 97213 United States, Pennsylvania University of Pittsburgh Cancer Institute / UPMC CancerCenter Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT01232660 HIV Infection Phase 1 Unknown August 2014 United Kingdom ... More >> St Stephen's Centre Recruiting London, United Kingdom, SW10 9NH Less <<
NCT02942381 IgA Patients ... More >>Hydroxychloroquine Less << Phase 2 Completed - China, Beijing ... More >> Peking University First Hospital BeiJing, Beijing, China, 100034 Less <<
NCT02631252 Leukemia, Acute Myelogenous Phase 1 Terminated(Inability to accrue... More >>) Less << - United States, Pennsylvania ... More >> University of Pittsburgh Cancer Institute - Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT02124681 Insulin Resistance Phase 1 Completed - United States, Pennsylvania ... More >> UPMC Montefiore Hospital Pittsburgh, Pennsylvania, United States, 15234 Less <<
NCT01073852 Chronic Urticaria Not Applicable Withdrawn(withdrawn, not funde... More >>d) Less << - -
NCT03037437 Hepatocellular Cancer Phase 2 Recruiting December 2018 United States, Texas ... More >> University of Texas Health Cancer Center Recruiting San Antonio, Texas, United States, 78229 Contact: Epp Goodwin    210-450-5798    goodwine@uthscsa.edu Less <<
NCT02303405 Diabetes Mellitus Type 2 With ... More >>Hyperglycemia Less << Phase 2 Terminated(Investigator decisi... More >>on) Less << - United States, California ... More >> Charles Drew University of Medicine and Science Los Angeles, California, United States, 90059 Less <<
NCT00962845 Melanoma (Skin) Early Phase 1 Completed - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT01551069 Cutaneous Lupus Erythematosus-... More >>Systemic Lupus Erythematosus Less << Phase 3 Completed - Japan ... More >> Investigational Site Number 392017 Bunkyo-Ku, Japan Investigational Site Number 392022 Bunkyo-Ku, Japan Investigational Site Number 392011 Chuo-Ku, Kumamoto-Shi, Japan Investigational Site Number 392003 Chuo-Ku, Japan Investigational Site Number 392001 Fuchu-Shi, Japan Investigational Site Number 392008 Iruma-Gun, Japan Investigational Site Number 392009 Iruma-Gun, Japan Investigational Site Number 392005 Itabashi-Ku, Japan Investigational Site Number 392014 Kamogawa City, Japan Investigational Site Number 392019 Kanazawa-Shi, Japan Investigational Site Number 392007 Kitakyushu, Japan Investigational Site Number 392020 Maebashi-Shi, Japan Investigational Site Number 392012 Nagasaki-Shi, Japan Investigational Site Number 392010 Nagoya-Shi, Japan Investigational Site Number 392013 Nakagami-Gun, Japan Investigational Site Number 392006 Sagamihara-Shi, Japan Investigational Site Number 392018 Sagamihara-Shi, Japan Investigational Site Number 392002 Shinjuku-Ku, Japan Investigational Site Number 392023 Tomigusuku-Shi, Japan Investigational Site Number 392021 Uruma-Shi, Japan Investigational Site Number 392004 Wakayama-Shi, Japan Investigational Site Number 392016 Yokohama-Shi, Japan Less <<
NCT03540810 Primary Antiphospholipid Syndr... More >>ome Less << Phase 3 Not yet recruiting October 15, 2022 France ... More >> University Hospital Angers Active, not recruiting Angers, France, 49000 Less <<
NCT01537315 Kidney Failure, Chronic ... More >> Cardiovascular Disease Arteriosclerosis Less << Phase 2 Terminated(lack of funding) - United States, Arkansas ... More >> Central Arkansas Veterans Healthcare System Little Rock, Arkansas, United States, 72205 University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 United States, Florida University of Florida Gainesville, Florida, United States, 32610-0224 Less <<
NCT03165136 Recurrent Miscarriage ... More >> First Trimester Abortion Less << Phase 3 Recruiting February 1, 2023 France ... More >> CHU Besançon Not yet recruiting Besançon, France, 25030 Contact: Aude Bourtembourg-Matras       a1bourtembourg@chu-besancon.fr    CHRU de Brest Recruiting Brest, France, 29609 Contact: Elisabeth PASQUIER       elisabeth.pasquier@chu-brest.fr    Contact: Gisèle MARHIC       gisele.marhic@chu-brest.fr    CHU Estaing Not yet recruiting Clermont-Ferrand, France Contact: Denis Gallot       dgallot@chu-clermontferrand.fr    Hôpital Nord - Unité mère-enfant Not yet recruiting Marseille, France, 13015 Contact: Florence Bretelle       florence.bretelle@ap-hm.fr    CHU de Nantes Not yet recruiting Nantes, France, 44093 Contact: NORBERT WINER       norbert.winer@chu-nantes.fr    Hopital Port Royal Cochin Not yet recruiting Paris 14, France, 75679 Contact: Geneviève Plu-Bureau       genevieve.plu-bureau@aphp.fr    Hopital Saint Antoine Not yet recruiting Paris, France, 75012 Contact: Arsène Mekinian       arsene.mekinian@aphp.fr    CHG François Mitterand Not yet recruiting Pau, France, 64 000 Contact: Caroline Bohec       caroline.bohec@ch-pau.fr    Centre hospitalier de Cornouaille Not yet recruiting Quimper, France, 29000 Contact: Charles Bellot       c.bellot@ch-cornouaille.fr    CHU de Saint Etienne - Hôpital Nord Not yet recruiting Saint Etienne, France, 42 270 Contact: Céline Chauleur       celine.chauleur@chu-st-etienne.fr Less <<
NCT00726596 Prostate Cancer Phase 2 Unknown October 2016 United States, New Jersey ... More >> Cancer Institute of New Jersey at Hamilton Hamilton, New Jersey, United States, 08690 Carol G. Simon Cancer Center at Morristown Memorial Hospital Morristown, New Jersey, United States, 07962 Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Overlook Hospital Summit, New Jersey, United States, 07901 Cooper University Hospital Cancer Institute Voorhees, New Jersey, United States, 08043 Less <<
NCT02379650 Recurrent Pregnancy Loss ... More >> Miscarriage Less << Phase 2 Withdrawn(Testing required by ... More >>FDA for IND approval was too expensive to move forward with conduct of the study.) Less << July 2021 United States, Utah ... More >> Intermountain Healthcare Salt Lake City, Utah, United States, 84107 University of Utah Hospital Salt Lake City, Utah, United States, 84132 Less <<
NCT01573754 Porphyria Cutanea Tarda Phase 2 Recruiting August 2022 United States, Texas ... More >> University of Texas Medical Branch Recruiting Galveston, Texas, United States, 77555 Contact: Karl E Anderson, MD    409-772-4661    kanderso@utmb.edu    Contact: Csilla K Hallberg, MD    409-772.4661    challberg@utmb.edu    Principal Investigator: Karl E Anderson, MD Less <<
NCT01537315 - Terminated(lack of funding) - -
NCT01326533 Pre-diabetes Phase 4 Completed - United States, Pennsylvania ... More >> University of Pittsburgh, Montefiore Hospital Pittsburgh, Pennsylvania, United States, 15213 Less <<
NCT01326533 - Completed - -
NCT02595346 Antiphospholipid Syndrome (APS... More >>) Less << Phase 2 Unknown December 2018 France ... More >> Rouen University Hospital Recruiting Rouen, France, 76031 Sub-Investigator: Ygal BENHAMOU, MD Less <<
NCT03316092 - Completed - Canada, Alberta ... More >> Dr. S.S. Michel Clinic Edmonton, Alberta, Canada, T5R5W9 Less <<
NCT01494155 Pancreatic Cancer Phase 2 Active, not recruiting January 2020 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Less <<
NCT02648464 Myocardial Infarction ... More >> Acute Coronary Syndrome Inflammation Hydroxychloroquine Antirheumatic Agents Cardiovascular Diseases Less << Phase 4 Recruiting December 2019 Finland ... More >> Helsinki University Central Hospital Recruiting Helsinki, Finland, 00290 Contact: Otto Hartman, MD       otto.hartman@helsinki.fi    Haartman Hospital Active, not recruiting Helsinki, Finland North Karelia Central Hospital Recruiting Joensuu, Finland Contact: Tuomas Rissanen, MD          Kymenlaakso Central Hospital Recruiting Kotka, Finland Contact: Jaana Yrjölä, MD          Päijät-Häme Central Hospital Recruiting Lahti, Finland Contact: Heli Tolppanen, MD          South Karelia Central Hospital Recruiting Lappeenranta, Finland Contact: Tuomo Nieminen, Professor          South Ostrobotnia Central Hospital Recruiting Seinäjoki, Finland Contact: Ismo Anttila, MD Less <<
NCT00771056 B-Cell Chronic Lymphocytic Leu... More >>kemia Less << Phase 2 Terminated(study suspended whi... More >>le data is reviewed for safety and efficacy.) Less << - United States, New York ... More >> Long Island Jewish Medical Center CLL Research and Treatment Center New Hyde Park, New York, United States, 11040 Less <<
NCT01842594 - Terminated(Most patients compl... More >>eted only the primary objective (PET) and not went throught the secondary outcome (efficacy phase) of 8wks period.) Less << - -
NCT01842594 Sarcoma Phase 2 Terminated(Most patients compl... More >>eted only the primary objective (PET) and not went throught the secondary outcome (efficacy phase) of 8wks period.) Less << - Taiwan ... More >> Shin Kong Wu Ho-Su Memorial Hospital Taipei, Taiwan, 11101 Less <<
NCT00771056 - Terminated(study suspended whi... More >>le data is reviewed for safety and efficacy.) Less << - -
NCT01379573 Congenital Heart Block ... More >> Neonatal Lupus Autoantibody-Associated Heart Block Less << Phase 2 Recruiting August 2019 United States, New York ... More >> New York University School of Medicine Recruiting New York, New York, United States, 10016 Contact: Jill P Buyon, MD    212-263-0746    jill.buyon@nyumc.org    Contact: Tishaun Middleton    646-501-0578    tishaun.middleton@nyumc.org    Principal Investigator: Jill P. Buyon, MD Less <<
NCT00632866 Primary Sj?gren's Syndrome Phase 3 Completed - France ... More >> Hopital Bicëtre Le Kremlin Bicetre, France, 94275 Less <<
NCT00946790 Immunosuppression ... More >> Rheumatism Less << Phase 1 Completed - -
NCT01132118 - Completed - -
NCT01266057 Advanced Cancers Phase 1 Active, not recruiting April 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02026232 Type 2 Diabetes Mellitus Not Applicable Recruiting December 2018 United States, Missouri ... More >> Washington University Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stacy Hurst, BSN, RN    314-747-3294    shurst@wustl.edu    Contact: Janet B. McGill, M.D.    (314) 362-8681    jmcgill@wustl.edu    Principal Investigator: Clay F. Semenkovich, M.D.          Sub-Investigator: Janet B. McGill, M.D. Less <<
NCT01601028 Autoimmune Diseases ... More >> Sjogren's Syndrome Dry Eye Less << Phase 3 Completed - Korea, Republic of ... More >> Seoul National Unversity Hospital Seoul, Korea, Republic of, 110-744 Less <<
NCT01784523 Antiphospholipid Syndrome Phase 3 Terminated(low recruitment rat... More >>e exacerbated by manufacturing shortage and price increase of hydroxychloroquine.) Less << - United States, New York ... More >> Hospital for Special Surgery New York, New York, United States, 10021 Less <<
NCT01132118 Rheumatoid Arthritis ... More >> Insulin Resistance Less << Phase 3 Completed - United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Less <<
NCT01144169 Renal Cell Carcinoma Phase 1 Terminated(barriers to accrual... More >> delay until surgery and additional pre-operative visits) Less << - United States, Pennsylvania ... More >> UPCI/UPMC Cancer Centers Pittsburgh, Pennsylvania, United States, 15232 UPMC Department of Urology Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT03283566 Chronic Pancreatitis ... More >> Insulin Dependent Diabetes Less << Phase 2 Recruiting October 3, 2019 United States, Ohio ... More >> Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Mario Scarcipino    216-444-3599    mascar@ccf.org    Principal Investigator: Betul Hatipoglu, MD Less <<
NCT03081702 Platinum-resistant Epithelial ... More >>Ovarian Cancer Less << Phase 1 Phase 2 Recruiting October 1, 2022 Canada, Ontario ... More >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Stephanie Lheureux, M.D.    416-946-2818 Less <<
NCT02913157 Multiple Sclerosis, Primary Pr... More >>ogressive Less << Phase 2 Recruiting December 2020 Canada, Alberta ... More >> MS Clinic Foothills Medical Centre Recruiting Calgary, Alberta, Canada, T2N2T9 Contact: Sharanjit Kaur    4039442579    sharanjit.kaur2@ahs.ca    Principal Investigator: Marcus Koch, MD, PhD Less <<
NCT02765594 Primary IgA Nephropathy Phase 4 Recruiting June 2019 China ... More >> Peing Union Medical College Hospital Recruiting Beijing, China, 100730 Contact: Ruitong Gao, MD    86-010-69155058    gaoruitong@gmail.com Less <<
NCT01273805 Pancreatic Cancer Phase 2 Completed - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Less <<
NCT02351752 Primary IgA Nephropathy Phase 4 Completed - China, Beijing ... More >> Peking University First Hospital BeiJing, Beijing, China, 100034 Less <<
NCT01273805 - Completed - -
NCT01687179 Lymphangioleiomyomatosis Phase 1 Completed - United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02120 Less <<
NCT01760421 Hashimoto Thyroiditis Not Applicable Completed - Taiwan ... More >> Department of Internal Medicine, National Taiwan University Hospital Taipei, Taiwan, 100 Less <<
NCT02126683 Hashimoto's Thyroiditis Not Applicable Unknown September 2016 Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan, 100 Less <<
NCT03428945 Type1 Diabetes Mellitus Phase 2 Recruiting August 2024 United States, Colorado ... More >> Barbara Davis Center Recruiting Aurora, Colorado, United States, 80045 Contact: Betsy Burke    303-724-6766    Betsy.Burke@ucdenver.edu    Principal Investigator: Andrea Steck, MD          United States, Florida University of Florida Recruiting Gainesville, Florida, United States, 32610 Contact: Jennifer Hosford    352-294-5759    jennifer.hosford@medicine.ufl.edu    Contact: Paula Towe    352-294-5761    pdtowe@peds.ufl.edu    Principal Investigator: Desmond Schatz, MD          University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Della Matheson    305-243-3781    dmatheso@med.miami.edu    Contact: Natalia Sanders-Branca    305-243-6616    n.sanders1@med.miami.edu    Principal Investigator: David Baidal, MD          United States, Pennsylvania University of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15224 Contact: David Groscost    412-692-7241    david.groscost@chp.edu    Contact: Kelli Delallo    412-692-5210    kelli.delallo@chp.edu    Principal Investigator: Dorothy Becker, MD          United States, Tennessee Vanderbilt Eskind Diabetes Clinic Recruiting Nashville, Tennessee, United States, 37232 Contact: Brenna Dixon    615-337-9597    brenna.dixon@vanderbilt.edu    Contact: Faith Brendle    615-936-8638    faith.brendle@vanderbilt.edu    Principal Investigator: William Russell, MD          United States, Texas University of Texas Southwestern Recruiting Dallas, Texas, United States, 75390 Contact: Lauren Boyles    241-648-4717    lauren.boyles@utsouthwestern.edu    Principal Investigator: Philip Raskin, MD          United States, Washington Benaroya Research Institute Recruiting Seattle, Washington, United States, 98101 Contact: Mary Ramey    206-342-6945    mramey@benaroyaresearch.org    Contact: Marli McCulloch-Olson    206-515-5239    Marli@benaroyaresearch.org    Principal Investigator: Carla Greenbaum, MD Less <<
NCT01687179 - Completed - -
NCT03275870 Hidradenitis Suppurativa ... More >> Hidradenitis Acne Inversa Boils Follicular Occlusion Triad Follicular Occlusion Tetrad Less << Phase 1 Phase 2 Recruiting June 2019 United States, Pennsylvania ... More >> University of Pittsburgh Recruiting Pittsburgh, Pennsylvania, United States, 15213 Contact: Elena M Gonzalez Brant, MD    412-647-4200    gonzalezbrantem@upmc.edu    Principal Investigator: Elena M Gonzalez Brant, MD          Sub-Investigator: Oleg Akilov, MD, PhD Less <<
NCT02874287 Coronary Artery Disease Phase 4 Recruiting May 2018 China, Shanxi ... More >> First Affiliated Hospital of Xi'an Jiaotong University Recruiting Xi'an, Shanxi, China Contact: Yue Wu, Professor    0086-029-8532-3664    imyuewu@qq.com Less <<
NCT02414776 Estrogen Receptor Positive Bre... More >>ast Cancer Less << Phase 1 Terminated(PI Leaving Site) - United States, Arizona ... More >> Western Regional Medical Center, Inc. Goodyear, Arizona, United States, 85338 Less <<
NCT01773616 Systemic Lupus Erythematosus, ... More >>Lupus Nephritis Less << Phase 3 Terminated(Study assessments f... More >>or patients recruited continuing per protocol so patients receive a minimum of 6 months follow up. No safety concerns have been raised.) Less << - United Kingdom ... More >> Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom, B15 2TH Chapel Allerton Hospital, The Leeds Teaching Hospitals NHS Trust Leeds, United Kingdom, LS7 4SA Leicester General Hospital, University Hospitals of Leicester NHS Trust Leicester, United Kingdom, LE5 4PW Royal Free London NHS Foundation Trust London, United Kingdom, NW3 2QG Guy's and St Thomas' NHS Foundation Trust London, United Kingdom, SE1 7EH Hammersmith Hospital, Imperial College Healthcare NHS Trust London, United Kingdom, W12 0HS Great Ormond Street Hospital for Children NHS Foundation Trust London, United Kingdom, WC1N 3JN King's College Hospital London, United Kingdom Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust Manchester, United Kingdom, M13 9WL Churchill Hospital, Oxford University Hospitals NHS Trust Oxford, United Kingdom, OX3 7LE Royal Stoke Hospital, University Hospitals of North Midlands NHS Trust Stoke-on-Trent, United Kingdom, ST4 6QG Less <<
NCT01557348 - Completed - -
NCT01557348 - Completed - -
NCT04491994 Covid19|Progression PHASE3 COMPLETED 2020-05-31 Pak Emirates Military Hospital... More >>, Rawalpindi, Punjab, 46000, Pakistan Less <<
NCT04911816 Adenocarcinoma of the Pancreas PHASE1|PHASE2 RECRUITING 2025-06-28 West Virginia University Cance... More >>r Institute Mary Babb Randolph Cancer Center, Morgantown, West Virginia, 26506, United States Less <<
NCT02013778 Hepatocellular Carcinoma PHASE1|PHASE2 TERMINATED 2025-02-19 Abramson Cancer Center of the ... More >>University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.52mL

2.30mL

1.15mL

23.04mL

4.61mL

2.30mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories